VLS Retatrutide Pen
VLS Retatrutide Pen
In short 产品简述
Retatrutide is a next-generation triple agonist peptide targeting GLP-1, GIP, and glucagon receptors. This VLS pre-filled pen offers precise, convenient administration for metabolic and weight management research.
Specifications 规格参数
About the Product 产品详情
Janoshik Lab Verified
Independent third-party testing
Purity
6.52mg/ml
Content
🔗 Verify at
janoshik.com/verify
using key:
2HPDNTUWCH9K
| Tested: Sept 2025
VLS Retatrutide Pen
is a next-generation
triple agonist peptide
targeting GLP-1, GIP, and glucagon receptors simultaneously. This pre-filled
Retatrutide injection pen
offers convenient, precise administration for research into weight management, metabolic health, and appetite regulation. Available for
UK delivery
with fast dispatch.
Retatrutide Pen Specifications
Peptide
Retatrutide
Type
Triple Agonist
Format
Pre-filled Pen
Concentration
6.66mg/ml
Purity
Brand
VLS
VLS Retatrutide 20mg
Pre-filled Injection Pen
Retatrutide Research Benefits
Triple receptor action
Appetite regulation
Metabolic health
Weight management
Convenient format
How Retatrutide Works
Retatrutide
is a novel
triple agonist peptide
that activates three key receptors involved in metabolic regulation: GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and the glucagon receptor. This multi-receptor approach differentiates it from single or dual agonists like semaglutide or tirzepatide.
By targeting all three pathways, Retatrutide research has shown potential for enhanced effects on appetite suppression, glucose metabolism, and energy expenditure. Clinical trials have demonstrated significant interest in its application for obesity and type 2 diabetes research.
Retatrutide vs Tirzepatide vs Semaglutide
While
Semaglutide
targets only GLP-1 and
Tirzepatide
targets GLP-1 and GIP,
Retatrutide
adds glucagon receptor activation for a triple-action approach. Early research suggests this may offer advantages in metabolic studies, making Retatrutide pens increasingly sought after for laboratory investigation.
⚠️ FOR LABORATORY RESEARCH USE ONLY
NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE
Safety Classification:
Legal Notice:
This product is exclusively intended for in vitro laboratory research conducted in controlled environments by qualified research staff. It is not for pharmaceutical, domestic, or any other applications. The purchaser accepts that acquiring and using this material is governed by all relevant UK regulations concerning research chemicals.
Third-Party Testing 第三方检测
What's in the Box 包装清单
- 1 × 预充注射笔
- 配套密封笔尖（数量以供应商包装为准）
Usage 使用说明
- 每次使用更换全新密封笔尖
- 旋拧刻度并核对剂量窗口
- 按研究方案设定的剂量给药
Handling & Storage 储存条件
- 2-8°C 冷藏，勿冷冻
- 避光保存于原包装盒内
- 首次启用后按供应商建议的期限内使用
Applications 应用方向
For research purposes only 免责声明
本条目信息整理自公开销售页面（The Ped Shop），仅供研究与信息参考。所列产品按研究用途展示，不作为药品或保健品销售，不用于诊断、治疗、治愈或预防任何疾病。实际规格、价格与库存以供应商页面为准。
Janoshik Lab Verified
Independent third-party testing
Purity
6.52mg/ml
Content
🔗 Verify at
janoshik.com/verify
using key:
2HPDNTUWCH9K
| Tested: Sept 2025
VLS Retatrutide Pen
is a next-generation
triple agonist peptide
targeting GLP-1, GIP, and glucagon receptors simultaneously. This pre-filled
Retatrutide injection pen
offers convenient, precise administration for research into weight management, metabolic health, and appetite regulation. Available for
UK delivery
with fast dispatch.
Retatrutide Pen Specifications
Peptide
Retatrutide
Type
Triple Agonist
Format
Pre-filled Pen
Concentration
6.66mg/ml
Purity
Brand
VLS
VLS Retatrutide 20mg
Pre-filled Injection Pen
Retatrutide Research Benefits
Triple receptor action
Appetite regulation
Metabolic health
Weight management
Convenient format
How Retatrutide Works
Retatrutide
is a novel
triple agonist peptide
that activates three key receptors involved in metabolic regulation: GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and the glucagon receptor. This multi-receptor approach differentiates it from single or dual agonists like semaglutide or tirzepatide.
By targeting all three pathways, Retatrutide research has shown potential for enhanced effects on appetite suppression, glucose metabolism, and energy expenditure. Clinical trials have demonstrated significant interest in its application for obesity and type 2 diabetes research.
Retatrutide vs Tirzepatide vs Semaglutide
While
Semaglutide
targets only GLP-1 and
Tirzepatide
targets GLP-1 and GIP,
Retatrutide
adds glucagon receptor activation for a triple-action approach. Early research suggests this may offer advantages in metabolic studies, making Retatrutide pens increasingly sought after for laboratory investigation.
⚠️ FOR LABORATORY RESEARCH USE ONLY
NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE
Safety Classification:
Legal Notice:
This product is exclusively intended for in vitro laboratory research conducted in controlled environments by qualified research staff. It is not for pharmaceutical, domestic, or any other applications. The purchaser accepts that acquiring and using this material is governed by all relevant UK regulations concerning research chemicals.